Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SB-568859 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| SB-568859 | DRUG | - |
Inclusion Criteria: * Healthy men and sterile women between 18 and 50 years old * Body weight greater than 50 pounds and a body mass index between 19 and 31 * Normal electrocardiogram Exclusion criteria: * No history of asthma or severe allergic reactions * No history of or current drug use * No ...
Top 10 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 7 | PHASE3 | Ziltivekimab, Zenagamtide |
| Eli Lilly and Company | LLY | 6 | PHASE3 | Lepodisiran, Retatrutide, Muvalaplin, Orforglipron, Clazakizumab |
| Novartis AG Sponsored ADR | NVS | 8 | PHASE3 | Inclisiran, Pelacarsen |
| Amgen Inc. | AMGN | 4 | PHASE3 | Olpasiran, Maridebart cafraglutide |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Enlicitide |
| NewAmsterdam Pharma Company N.V. | NAMS | 2 | PHASE3 | Obicetrapib |
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Roivant Sciences Ltd. | ROIV | 3 | PHASE3 | Mosliciguat |
| Genentech, Inc. | RHHBY | 1 | PHASE2 | Selnoflast |
| Verve Therapeutics, Inc. | VERV | 2 | PHASE2 | VERVE-102 |
SB-568859 is an investigational small molecule being developed for atherosclerosis, a cardiovascular condition characterized by the buildup of plaque in the arteries. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
SB-568859 is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics in humans.
SB-568859 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved for use in patients. The Phase 1 trial has been completed, and the drug is still in the early stages of clinical testing.
SB-568859 has one completed Phase 1 clinical trial registered under NCT00470145. The study, titled 'Comparison Of Two Tablet Formulations Of SB-568859,' enrolled 28 participants in the United States and evaluated the drug in healthy volunteers.
SB-568859 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for atherosclerosis. The completed Phase 1 trial was designed to assess the drug's safety and formulation, but it has not yet received regulatory approval for marketing.